The early release article by Pivot et al, entitled "CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Patients with early breast cancer when trastuzumab was given as neoadjuvant therapy (RR, 1.30; 95% CI, 0.47-3.59; with consistency across studies, I2 = 0%; P =.57).

The open-label, multicenter DESTINY-PanTumor02 trial assessed the antibody-drug conjugate at a dose of 5.4 mg/kg every 3 weeks among 267 patients (average age, 62 years; 61% white, 32.6% Asian ...

Publisher’s Note The article by Ostwal et al entitled “Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A ...

Send comments and news tips to [email protected]. Cite this: Edited by Katie Lennon. Trastuzumab Duocarmazine Ups PFS, Ocular Toxicity in Advanced HER2+ Breast Cancer - Medscape - October 31, 2024.

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label ...